We want to be very clear about what our position has always been: Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so. Once we are certified by the FDA, we will dispense
Nexcella, Inc. ("Nexcella", "Company", "We" or "Us"), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other
NeoGames (NASDAQ: NGMS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.13) by 269.23 percent. This is a 257.14 percent increase over losses of $(0.14) per share from the same period last year.